<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Etiology of osteoporosis in men</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Etiology of osteoporosis in men</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Etiology of osteoporosis in men</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joel S Finkelstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elaine W Yu, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Osteoporosis is a common disease that is characterized by low bone mass with microarchitectural disruption and skeletal fragility, resulting in an increased risk of fracture. It is a leading cause of morbidity and mortality in older people.</p><p>The disorders that cause osteoporosis in men are similar to those in women  (<a class="graphic graphic_table graphicRef60440" href="/z/d/graphic/60440.html" rel="external">table 1</a>). Epidemiologic surveys suggest that causes or contributing factors for osteoporosis can be identified in 40 to 60 percent of men who have osteoporotic fractures [<a href="#rid1">1-3</a>]. Hypogonadism, glucocorticoid therapy, gastrointestinal disease, vitamin D deficiency, antiseizure medication therapy, hypercalciuria, and alcohol use disorder were among the most common identifiable causes of osteoporosis in these surveys [<a href="#rid2">2-5</a>].</p><p>The etiology of osteoporosis in men will be reviewed here. The epidemiology of osteoporosis, fracture risk assessment, and the evaluation and treatment of osteoporosis in men are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment"</a> and  <a class="medical medical_review" href="/z/d/html/2052.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men"</a> and  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Decreased bone mass can occur either because pubertal bone accretion is reduced or because the rate of bone resorption is accelerated after peak bone mass is achieved. Both of these processes are likely to contribute, in varying degrees, to osteoporosis in individual patients. (See  <a class="medical medical_review" href="/z/d/html/2044.html" rel="external">"Pathogenesis of osteoporosis"</a>.)</p><p class="headingAnchor" id="H1633597954"><span class="h2">Peak bone mass acquisition</span><span class="headingEndMark"> — </span>Peak bone mass is the maximum bone mass achieved in life. The time of peak bone mass is not known with certainty, but probably occurs in the third decade of life in most individuals, with differences in timing due to genetic, hormonal, and environmental variables. (See  <a class="medical medical_review" href="/z/d/html/2044.html" rel="external">"Pathogenesis of osteoporosis", section on 'Peak bone mass acquisition'</a>.)</p><p>In men, bone mineral density (BMD) increases markedly during puberty in response to increasing sex steroid production [<a href="#rid6">6,7</a>]. Much of this apparent increase, particularly for cortical bone, is due to an increase in bone size. Peak spinal bone density is reached at approximately 20 years of age [<a href="#rid8">8-10</a>], while the peak density of the radius and femoral shaft is reached somewhat later [<a href="#rid9">9-11</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex steroids</strong> – The importance of normal sex steroid production in the acquisition of peak bone mass is illustrated by the findings of low bone mass in young men with idiopathic hypogonadotropic hypogonadism (IHH), a congenital disorder of gonadotropin-releasing hormone (GnRH) deficiency (see  <a class="medical medical_review" href="/z/d/html/7465.html" rel="external">"Isolated gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)"</a>). In studies of men with IHH who do not undergo puberty unless they are treated appropriately, both cortical and trabecular bone density are markedly reduced [<a href="#rid12">12,13</a>]. Bone mass is reduced even during the period of rapid bone accrual before peak adult BMD is reached, suggesting that the finding of low BMD in adult men with IHH is due to inadequate pubertal bone accretion rather than excessive post-maturity bone loss. Although the observation that peak BMD is reduced in men with IHH illustrates the importance of gonadal steroids in pubertal bone accrual, that finding does not indicate whether androgens, estrogens, or both are primarily responsible for the pubertal increase in BMD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Androgens versus estrogens</strong> – Both estrogens and androgens have profound effects on bone homeostasis in men. Individuals with mutations that lead to complete estrogen or androgen insensitivity provide valuable insights into the independent roles of androgens and estrogens in the attainment of peak bone mass. For example, the observation that BMD is markedly reduced in men with null mutations in the estrogen receptor gene demonstrates that estrogens play a key role in the attainment of peak bone mass in men. Similarly, the marked reduction in BMD in men with null mutations in the androgen receptor gene demonstrates that androgens also play a key role in the attainment of peak bone mass. (See  <a class="medical medical_review" href="/z/d/html/7458.html" rel="external">"Pathogenesis and clinical features of disorders of androgen action", section on 'Complete androgen insensitivity (CAIS)'</a> and  <a class="medical medical_review" href="/z/d/html/2044.html" rel="external">"Pathogenesis of osteoporosis", section on 'Sex steroid deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of puberty</strong> – Another important determinant of peak bone density is the timing of puberty. In adult men with a history of constitutionally delayed puberty, BMD of the radius, lumbar spine, and proximal femur is significantly lower than in age-matched normal men, and BMD does not appear to normalize even after sex steroid production is restored [<a href="#rid14">14,15</a>]. Similar findings have been reported in adolescent boys with delayed puberty [<a href="#rid16">16</a>]. These observations suggest that there is a critical period of time during which gonadal steroids are needed in order to achieve optimal peak BMD in men. (See  <a class="medical medical_review" href="/z/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty"</a>.)</p><p></p><p class="headingAnchor" id="H591901767"><span class="h2">Age-related bone loss</span><span class="headingEndMark"> — </span>After attainment of peak bone mass, men lose approximately 30 percent of their trabecular bone and 20 percent of their cortical bone during their lifetimes. Trabecular bone loss appears to start shortly after peak BMD is reached whereas cortical bone loss begins somewhat later [<a href="#rid17">17</a>]. Acceleration of age-related bone loss can occur either when bone resorption is increased or when bone formation is impaired during skeletal remodeling.</p><p>When spine BMD is measured [<a href="#rid18">18,19</a>] using dual-energy x-ray absorptiometry (DXA) in the posterior-anterior projection, it often appears to increase in older men [<a href="#rid20">20-22</a>], likely due to degenerative changes in the posterior spinous elements  (<a class="graphic graphic_figure graphicRef53843" href="/z/d/graphic/53843.html" rel="external">figure 1</a>) [<a href="#rid21">21</a>]. This limitation of posterior-anterior spine DXA for evaluation of spine BMD in older men can be circumvented by measuring lateral spine BMD by DXA or by assessing spine BMD using quantitative computed tomography (QCT) to assess trabecular BMD without including the posterior spinous elements. (See  <a class="medical medical_review" href="/z/d/html/2056.html" rel="external">"Overview of dual-energy x-ray absorptiometry", section on 'Clinical applications of DXA'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex steroids</strong> – Although gonadal steroids appear to play a crucial role in the attainment of peak bone mass in men, whether they play a significant role in age-related bone loss is less clear. Unlike in women, in whom the menopause marks the end of robust estradiol production, the rate of age-related gonadal steroid decline is much less abrupt in men, and most men maintain normal adult levels of testosterone throughout life. As a result, men do not undergo a period of rapid bone loss as seen in women at the onset of the menopause. The skeletal impact of these more subtle declines in sex steroids is unclear. Several approaches have been used to assess the role of gonadal steroids in adult bone loss.</p><p></p><p class="bulletIndent1">Numerous epidemiologic studies have reported associations between gonadal sex steroids and BMD or fractures [<a href="#rid23">23-27</a>]. Overall, these epidemiologic associations are weak, however, as might be expected when studying different populations and relating a single hormone measurement to complex endpoints like bone density and fracture.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Testosterone</strong> – Some studies have reported significant associations between testosterone, free testosterone, and/or bioavailable testosterone and BMD, rates of bone loss, and prevalent fragility fractures [<a href="#rid23">23-25</a>] whereas others have not [<a href="#rid26">26,28</a>]. For example, in the Osteoporotic Fractures in Men Study (MrOS), a cross-sectional and longitudinal study of 2447 men over 65 years of age, the prevalence of osteoporosis in the hip or of rapid hip bone loss was threefold higher in men whose total testosterone level was &lt;200 ng/dL (6.9 nmol/L) compared with men whose serum testosterone level was higher  (<a class="graphic graphic_figure graphicRef68642" href="/z/d/graphic/68642.html" rel="external">figure 2</a>) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Estrogen</strong> – In general, associations of bone density with estrogens have been slightly stronger than associations with androgens [<a href="#rid26">26</a>]. In the MrOS study, the prevalence of osteoporosis in the hip (T-score &lt;-2.5) increased progressively as total or bioavailable estradiol levels fell  (<a class="graphic graphic_figure graphicRef68642" href="/z/d/graphic/68642.html" rel="external">figure 2</a>) [<a href="#rid23">23</a>]. In addition, low serum estradiol levels have been associated with an increased risk of future hip fracture in men [<a href="#rid27">27</a>]. Fracture risk appears to be even greater in men with both low serum estradiol and testosterone concentrations [<a href="#rid26">26,27</a>].</p><p></p><p class="bulletIndent1">Several physiologic studies have concluded that regulation of bone turnover in adult men is primarily accomplished by estrogen [<a href="#rid29">29-31</a>]. In one physiologic study, 198 healthy men (ages 20 to 50 years) were treated with a GnRH agonist (to temporarily suppress endogenous sex steroid production) and were then randomized to receive 0 (placebo), 1.25, 2.5, 5, or 10 grams of a testosterone gel daily for 16 weeks [<a href="#rid31">31</a>]. A second group of 202 healthy men received the same doses of testosterone as well as <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a> (to suppress aromatization of testosterone to estradiol). By comparing changes in bone turnover markers, BMD by DXA, and BMD by QCT between men who did and did not receive anastrozole, the study demonstrated that increases in bone resorption and decreases in BMD in hypogonadal men were largely due to estrogen deficiency  (<a class="graphic graphic_figure graphicRef122914" href="/z/d/graphic/122914.html" rel="external">figure 3</a>). The risk of developing hypogonadal bone loss appeared to be small until serum estradiol levels fell below 10 pg/mL and/or serum testosterone levels fell below 200 ng/dL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other hormones</strong> – Other hormonal changes that may be associated with age-related bone loss include higher serum parathyroid hormone (PTH) concentrations and lower serum 25-hydroxyvitamin D and insulin-like growth factor 1 (IGF-1) concentrations [<a href="#rid32">32-34</a>]. Suppression of gonadal steroids in older men with a GnRH agonist increases the skeletal responsiveness to pharmacologic doses of exogenous PTH, an observation that might help to explain bone loss in men with hypogonadism [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/2053.html" rel="external">"Normal skeletal development and regulation of bone formation and resorption", section on 'Systemic and local regulators of bone cells'</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The medical disorders that cause osteoporosis in men are similar to those in women  (<a class="graphic graphic_table graphicRef60440" href="/z/d/graphic/60440.html" rel="external">table 1</a>). Epidemiologic surveys suggest that secondary causes for osteoporosis can be identified in 40 to 60 percent of men who have osteoporotic fractures [<a href="#rid1">1-3</a>]. Hypogonadism, glucocorticoid therapy, gastrointestinal disease, vitamin D deficiency, low body mass index (BMI), antiseizure medication therapy, hypercalciuria, diabetes mellitus, current smoking, and alcohol use disorder were among the most common identifiable causes of osteoporosis in these surveys [<a href="#rid2">2-5,36</a>].</p><p>Risk factors that have been demonstrated to be most predictive of osteoporotic fractures in men include low bone mineral density (BMD), advancing age, a prior history of fragility fracture, chronic glucocorticoid use, and parental history of hip fracture  (<a class="graphic graphic_figure graphicRef122916" href="/z/d/graphic/122916.html" rel="external">figure 4</a>) [<a href="#rid36">36,37</a>]. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Clinical risk factor assessment'</a>.)</p><p>Brief comments on some of the etiologies follow; more detailed reviews are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2032.html" rel="external">"Clinical features and evaluation of glucocorticoid-induced osteoporosis"</a> and  <a class="medical medical_review" href="/z/d/html/7882.html" rel="external">"Bone disease with hyperthyroidism and thyroid hormone therapy"</a> and  <a class="medical medical_review" href="/z/d/html/2051.html" rel="external">"Bone disease in diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/2028.html" rel="external">"Metabolic bone disease in inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/z/d/html/2036.html" rel="external">"Drugs that affect bone metabolism"</a>.)</p><p class="headingAnchor" id="H1525134674"><span class="h2">Hypogonadism</span><span class="headingEndMark"> — </span>Gonadal steroids play an important role in attainment and maintenance of BMD in men (see <a class="local">'Peak bone mass acquisition'</a> above and <a class="local">'Age-related bone loss'</a> above). Bone turnover increases and BMD decreases in men with serum testosterone levels that are below approximately 200 ng/dL, likely because serum estradiol levels fall below 10 to 15 pg/mL [<a href="#rid31">31</a>].</p><p>Cross-sectional studies demonstrate that BMD is reduced in men with primary or secondary hypogonadism [<a href="#rid12">12,38-42</a>], constitutional delay of puberty [<a href="#rid14">14,15</a>], idiopathic hypogonadotropic hypogonadism (IHH) [<a href="#rid12">12,13</a>], and in individuals with androgen insensitivity [<a href="#rid43">43,44</a>]. (See  <a class="medical medical_review" href="/z/d/html/7459.html" rel="external">"Causes of primary hypogonadism in males"</a> and  <a class="medical medical_review" href="/z/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males"</a> and  <a class="medical medical_review" href="/z/d/html/7471.html" rel="external">"Diagnosis and treatment of disorders of the androgen receptor"</a>.)</p><p>Osteoporosis has also been reported in hypogonadal men with hemochromatosis [<a href="#rid39">39,45</a>] and anorexia nervosa [<a href="#rid46">46</a>]. In these men, it is difficult to determine whether the osteopenia is due to concomitant liver disease and nutritional deficiencies or to hypogonadism. (See  <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemochromatosis"</a>.)</p><p>There have been few longitudinal studies of men at risk for osteoporosis because of hypogonadism. Bone density decreases in young men who are castrated for sexual delinquency [<a href="#rid47">47</a>] and in older men with advanced prostate cancer who undergo androgen ablation therapy [<a href="#rid48">48-51</a>]. (See  <a class="medical medical_review" href="/z/d/html/6927.html" rel="external">"Side effects of androgen deprivation therapy", section on 'Osteoporosis and bone fractures'</a>.)</p><p>Severe hypogonadism increases the risk of fractures in men:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 235 men with prostate cancer, 14 percent of those treated with orchiectomy (n = 59) later had osteoporotic fractures, compared with 1 percent in those who did not undergo orchiectomy (n = 176) [<a href="#rid52">52</a>]. Among the 16 men who survived for at least five years after orchiectomy, six (38 percent) had a nontraumatic fracture that was not attributable to their cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The increase in fracture risk with androgen deprivation therapy (rather than orchiectomy) may be more modest. This was illustrated in a much larger study of 50,613 men with a diagnosis of prostate cancer; 19 percent of 6650 men who survived at least five years after diagnosis (and who received androgen-deprivation therapy) had a fracture (compared with 12 percent of the 20,035 patients who did not receive androgen-deprivation therapy) [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1">Reduction in BMD can be detected after as little as six to nine months of androgen deprivation therapy. Thus, all men beginning such therapy should receive calcium and vitamin D and maintain a moderate exercise regimen [<a href="#rid54">54</a>]. Treatment with calcium and vitamin D alone, however, is not sufficient to prevent bone loss in these men. Baseline measurement of bone density and periodic reassessment during therapy are appropriate, and bisphosphonate therapy should be considered. (See  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men"</a> and  <a class="medical medical_review" href="/z/d/html/6927.html" rel="external">"Side effects of androgen deprivation therapy", section on 'Osteoporosis and bone fractures'</a>.)</p><p></p><p class="headingAnchor" id="H1577941988"><span class="h2">Lifestyle factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking and alcohol</strong> – Both cigarette smoking and excess alcohol intake are associated with increased rates of bone loss and fracture [<a href="#rid55">55,56</a>] (see  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Cigarette smoking'</a>). Alcohol intake is inversely associated with bone density in men [<a href="#rid57">57,58</a>], and osteoporotic fractures are common in men with alcohol use disorder [<a href="#rid3">3,59</a>]. The mechanism whereby alcohol reduces bone density is unknown but appears to be related to decreased bone formation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium and vitamin D</strong> – In observational studies, vitamin D deficiency is associated with osteoporosis, poor physical performance, and an increased risk of fractures [<a href="#rid4">4,33,60</a>]. Evidence supporting the benefit of calcium and vitamin D supplementation in men with osteoporosis comes largely from prospective, randomized, placebo-controlled trials [<a href="#rid61">61,62</a>]. Although a number of trials have reported a beneficial effect of calcium or calcium plus vitamin D on bone density in postmenopausal women and older men [<a href="#rid61">61-65</a>], the data on fracture rates are more variable [<a href="#rid66">66</a>]. This topic is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical activity and strength</strong> – Low levels of physical activity are associated with bone loss [<a href="#rid1">1,67-69</a>] and a higher risk of fracture in older men [<a href="#rid70">70-73</a>]. As an example, in a cohort study of 2205 men aged 49 to 51 years, low or medium levels of physical activity were associated with more than a twofold higher risk of fracture, including hip fracture, compared with high physical activity [<a href="#rid73">73</a>]. Hip fracture occurred in 20.5, 13.3, and 8.4 percent of men with sedentary lifestyle, medium physical activity, and high physical activity, respectively (hazard ratios [HRs] for low- or medium-activity compared with high-activity groups 2.56 [95% CI 1.55-4.24] and 1.61 [95% CI 1.10-2.36], respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Body weight</strong> – Body weight is positively associated with bone density in older men, and weight loss appears to increase the rate of hip bone loss, even in obese men undergoing voluntary weight reduction [<a href="#rid74">74</a>]. Low BMI is a well-known risk factor for fracture in men, just as in women [<a href="#rid75">75</a>].</p><p></p><p class="headingAnchor" id="H20"><span class="h2">Glucocorticoid excess</span><span class="headingEndMark"> — </span>Both endogenous and exogenous glucocorticoid excess cause osteoporosis in men as well as in women. The osteoporosis is due primarily to the effects of glucocorticoid excess on bone, but glucocorticoid-induced hypogonadism may be a contributory factor. Glucocorticoid excess, which is nearly always caused by exogenous glucocorticoid therapy, is responsible for approximately 15 percent of vertebral fractures in men [<a href="#rid3">3,76</a>], but some of the bone disease may be due to the underlying disorders for which glucocorticoids are given rather than the glucocorticoid therapy itself. (See  <a class="medical medical_review" href="/z/d/html/2032.html" rel="external">"Clinical features and evaluation of glucocorticoid-induced osteoporosis"</a>.)</p><p class="headingAnchor" id="H2844737005"><span class="h2">Diabetes mellitus</span><span class="headingEndMark"> — </span>Although type 2 diabetes mellitus is generally associated with higher bone density, men with diabetes suffer an increased risk of fractures [<a href="#rid77">77-79</a>] as compared with those without diabetes. As in women, fracture rates are highest among men with diabetes who take insulin [<a href="#rid80">80</a>], which likely reflects a combination of increased fall risk, greater diabetic severity, and microvascular disease burden, as well as compromised bone quality. (See  <a class="medical medical_review" href="/z/d/html/2051.html" rel="external">"Bone disease in diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Hypercalciuria</span><span class="headingEndMark"> — </span>Men with hypercalciuria may have lower BMD than expected for age, particularly those in whom hypercalciuria persists despite a low calcium diet [<a href="#rid81">81-86</a>].</p><p class="headingAnchor" id="H22"><span class="h2">Idiopathic osteoporosis</span><span class="headingEndMark"> — </span>The 40 to 60 percent of men with osteoporosis in whom a cause cannot be identified are said to have idiopathic osteoporosis. Histomorphometric studies suggest that many have diminished bone formation [<a href="#rid87">87-89</a>], but some have increased bone resorption [<a href="#rid90">90</a>]. Many of these men probably have a genetic predisposition to osteoporosis [<a href="#rid91">91</a>].</p><p>Serum insulin-like growth factor 1 (IGF-1) concentrations are low in some men with idiopathic osteoporosis (see  <a class="medical medical_review" href="/z/d/html/2053.html" rel="external">"Normal skeletal development and regulation of bone formation and resorption", section on 'Growth hormone and IGFs'</a>). Approximately 2 to 3 percent of men have a history of delayed puberty, which could be a precursor of idiopathic osteoporosis. Estrogen deficiency may also be responsible for otherwise unexplained osteoporosis in some men. (See <a class="local">'Pathophysiology'</a> above and <a class="local">'Hypogonadism'</a> above.)</p><p class="headingAnchor" id="H3090714654"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105492.html" rel="external">"Society guideline links: Osteoporosis"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Low bone mass in men may be due to suboptimal peak bone mass acquisition, ongoing bone loss, or reduced bone formation during remodeling. Normal sex steroid production is necessary for the acquisition of peak bone mass in men. The rate of age-related gonadal sex steroid decline in men is much less abrupt than in women, and most men maintain normal adult levels of testosterone throughout life. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – A cause for osteoporosis can be identified in 40 to 60 percent of men who have osteoporotic fractures. Hypogonadism, glucocorticoid therapy, gastrointestinal disease, vitamin D deficiency, antiseizure medication therapy, hypercalciuria, diabetes mellitus, and alcohol use disorder are among the most common identifiable causes of osteoporosis in men  (<a class="graphic graphic_table graphicRef60440" href="/z/d/graphic/60440.html" rel="external">table 1</a>). (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1">The risk factors most predictive of osteoporotic fracture in men include low bone mineral density (BMD), advancing age, a prior history of fragility fracture, chronic glucocorticoid use, and parental history of hip fracture  (<a class="graphic graphic_figure graphicRef122916" href="/z/d/graphic/122916.html" rel="external">figure 4</a>).</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995; 16:87.</a></li><li><a class="nounderline abstract_t">Kelepouris N, Harper KD, Gannon F, et al. Severe osteoporosis in men. Ann Intern Med 1995; 123:452.</a></li><li><a class="nounderline abstract_t">Seeman E, Melton LJ 3rd, O'Fallon WM, Riggs BL. Risk factors for spinal osteoporosis in men. Am J Med 1983; 75:977.</a></li><li><a class="nounderline abstract_t">Diamond T, Smerdely P, Kormas N, et al. Hip fracture in elderly men: the importance of subclinical vitamin D deficiency and hypogonadism. Med J Aust 1998; 169:138.</a></li><li><a class="nounderline abstract_t">Scane AC, Francis RM, Sutcliffe AM, et al. Case-control study of the pathogenesis and sequelae of symptomatic vertebral fractures in men. Osteoporos Int 1999; 9:91.</a></li><li><a class="nounderline abstract_t">Krabbe S, Christiansen C. Longitudinal study of calcium metabolism in male puberty. I. Bone mineral content, and serum levels of alkaline phosphatase, phosphate and calcium. Acta Paediatr Scand 1984; 73:745.</a></li><li><a class="nounderline abstract_t">Krabbe S, Hummer L, Christiansen C. Longitudinal study of calcium metabolism in male puberty. II. Relationship between mineralization and serum testosterone. Acta Paediatr Scand 1984; 73:750.</a></li><li><a class="nounderline abstract_t">Gilsanz V, Gibbens DT, Roe TF, et al. Vertebral bone density in children: effect of puberty. Radiology 1988; 166:847.</a></li><li><a class="nounderline abstract_t">Bonjour JP, Theintz G, Buchs B, et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991; 73:555.</a></li><li><a class="nounderline abstract_t">Theintz G, Buchs B, Rizzoli R, et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 1992; 75:1060.</a></li><li class="breakAll">Mazess RB, Cameron JR. Bone mineral content in normal U.S. whites. In: Proceedings, International Conference on Bone Mineral Measurement. Mazess, RB (Ed). DHEW Publication NIH 75-683, Washington, D.C. 1974; 228.</li><li><a class="nounderline abstract_t">Finkelstein JS, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987; 106:354.</a></li><li><a class="nounderline abstract_t">Guo CY, Jones TH, Eastell R. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover. J Clin Endocrinol Metab 1997; 82:658.</a></li><li><a class="nounderline abstract_t">Finkelstein JS, Neer RM, Biller BM, et al. Osteopenia in men with a history of delayed puberty. N Engl J Med 1992; 326:600.</a></li><li><a class="nounderline abstract_t">Finkelstein JS, Klibanski A, Neer RM. A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. J Clin Endocrinol Metab 1996; 81:1152.</a></li><li><a class="nounderline abstract_t">Bertelloni S, Baroncelli GI, Battini R, et al. Short-term effect of testosterone treatment on reduced bone density in boys with constitutional delay of puberty. J Bone Miner Res 1995; 10:1488.</a></li><li><a class="nounderline abstract_t">Riggs BL, Melton LJ, Robb RA, et al. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res 2008; 23:205.</a></li><li><a class="nounderline abstract_t">Orwoll ES, Oviatt SK, McClung MR, et al. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med 1990; 112:29.</a></li><li><a class="nounderline abstract_t">Meier DE, Orwoll ES, Jones JM. Marked disparity between trabecular and cortical bone loss with age in healthy men. Measurement by vertebral computed tomography and radial photon absorptiometry. Ann Intern Med 1984; 101:605.</a></li><li><a class="nounderline abstract_t">Jones G, Nguyen T, Sambrook P, et al. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ 1994; 309:691.</a></li><li><a class="nounderline abstract_t">Zmuda JM, Cauley JA, Glynn NW, Finkelstein JS. Posterior-anterior and lateral dual-energy x-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men. J Bone Miner Res 2000; 15:1417.</a></li><li><a class="nounderline abstract_t">Orwoll ES, Oviatt SK, Mann T. The impact of osteophytic and vascular calcifications on vertebral mineral density measurements in men. J Clin Endocrinol Metab 1990; 70:1202.</a></li><li><a class="nounderline abstract_t">Fink HA, Ewing SK, Ensrud KE, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 2006; 91:3908.</a></li><li><a class="nounderline abstract_t">Mellström D, Johnell O, Ljunggren O, et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 2006; 21:529.</a></li><li><a class="nounderline abstract_t">Ensrud KE, Lewis CE, Lambert LC, et al. Endogenous sex steroids, weight change and rates of hip bone loss in older men: the MrOS study. Osteoporos Int 2006; 17:1329.</a></li><li><a class="nounderline abstract_t">Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86:3555.</a></li><li><a class="nounderline abstract_t">Amin S, Zhang Y, Felson DT, et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med 2006; 119:426.</a></li><li><a class="nounderline abstract_t">Araujo AB, Travison TG, Leder BZ, McKinlay JB. Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men. J Clin Endocrinol Metab 2008; 93:2135.</a></li><li><a class="nounderline abstract_t">Falahati-Nini A, Riggs BL, Atkinson EJ, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000; 106:1553.</a></li><li><a class="nounderline abstract_t">Leder BZ, LeBlanc KM, Schoenfeld DA, et al. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 2003; 88:204.</a></li><li><a class="nounderline abstract_t">Finkelstein JS, Lee H, Leder BZ, et al. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest 2016; 126:1114.</a></li><li><a class="nounderline abstract_t">Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab 1999; 84:3626.</a></li><li><a class="nounderline abstract_t">Orwoll ES, Meier DE. Alterations in calcium, vitamin D, and parathyroid hormone physiology in normal men with aging: relationship to the development of senile osteopenia. J Clin Endocrinol Metab 1986; 63:1262.</a></li><li><a class="nounderline abstract_t">Rapado A, Hawkins F, Sobrinho L, et al. Bone mineral density and androgen levels in elderly males. Calcif Tissue Int 1999; 65:417.</a></li><li><a class="nounderline abstract_t">Leder BZ, Smith MR, Fallon MA, et al. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 2001; 86:511.</a></li><li><a class="nounderline abstract_t">Kanis JA, Oden A, Johansson H, et al. FRAX and its applications to clinical practice. Bone 2009; 44:734.</a></li><li><a class="nounderline abstract_t">Lewis CE, Ewing SK, Taylor BC, et al. Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 2007; 22:211.</a></li><li><a class="nounderline abstract_t">Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86:2787.</a></li><li><a class="nounderline abstract_t">Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med 1989; 110:430.</a></li><li><a class="nounderline abstract_t">Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81:4358.</a></li><li><a class="nounderline abstract_t">Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82:2386.</a></li><li><a class="nounderline abstract_t">Finkelstein JS, Klibanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69:776.</a></li><li><a class="nounderline abstract_t">Bertelloni S, Baroncelli GI, Federico G, et al. Altered bone mineral density in patients with complete androgen insensitivity syndrome. Horm Res 1998; 50:309.</a></li><li><a class="nounderline abstract_t">Marcus R, Leary D, Schneider DL, et al. The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome. J Clin Endocrinol Metab 2000; 85:1032.</a></li><li><a class="nounderline abstract_t">Diamond T, Stiel D, Posen S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J Bone Miner Res 1991; 6:39.</a></li><li><a class="nounderline abstract_t">Andersen AE, Watson T, Schlechte J. Osteoporosis and osteopenia in men with eating disorders. Lancet 2000; 355:1967.</a></li><li><a class="nounderline abstract_t">Stĕpán JJ, Lachman M, Zvĕrina J, et al. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989; 69:523.</a></li><li><a class="nounderline abstract_t">Chen Z, Maricic M, Nguyen P, et al. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 2002; 95:2136.</a></li><li><a class="nounderline abstract_t">Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345:948.</a></li><li><a class="nounderline abstract_t">Maillefert JF, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161:1219.</a></li><li><a class="nounderline abstract_t">Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002; 87:3656.</a></li><li><a class="nounderline abstract_t">Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157:439.</a></li><li><a class="nounderline abstract_t">Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352:154.</a></li><li><a class="nounderline abstract_t">Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002; 167:1952.</a></li><li><a class="nounderline abstract_t">Jutberger H, Lorentzon M, Barrett-Connor E, et al. Smoking predicts incident fractures in elderly men: Mr OS Sweden. J Bone Miner Res 2010; 25:1010.</a></li><li><a class="nounderline abstract_t">Drake MT, Murad MH, Mauck KF, et al. Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97:1861.</a></li><li><a class="nounderline abstract_t">Slemenda CW, Christian JC, Reed T, et al. Long-term bone loss in men: effects of genetic and environmental factors. Ann Intern Med 1992; 117:286.</a></li><li><a class="nounderline abstract_t">Dalén N, Lamke B. Bone mineral losses in alcoholics. Acta Orthop Scand 1976; 47:469.</a></li><li><a class="nounderline abstract_t">Spencer H, Rubio N, Rubio E, et al. Chronic alcoholism. Frequently overlooked cause of osteoporosis in men. Am J Med 1986; 80:393.</a></li><li><a class="nounderline abstract_t">Wicherts IS, van Schoor NM, Boeke AJ, et al. Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab 2007; 92:2058.</a></li><li><a class="nounderline abstract_t">Daly RM, Brown M, Bass S, et al. Calcium- and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomized controlled trial. J Bone Miner Res 2006; 21:397.</a></li><li><a class="nounderline abstract_t">Meier C, Woitge HW, Witte K, et al. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res 2004; 19:1221.</a></li><li><a class="nounderline abstract_t">Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337:670.</a></li><li><a class="nounderline abstract_t">Reid IR, Ames R, Mason B, et al. Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men. Arch Intern Med 2008; 168:2276.</a></li><li><a class="nounderline abstract_t">Peacock M, Liu G, Carey M, et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab 2000; 85:3011.</a></li><li><a class="nounderline abstract_t">Cranney A, Weiler HA, O'Donnell S, Puil L. Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health. Am J Clin Nutr 2008; 88:513S.</a></li><li><a class="nounderline abstract_t">Snow-Harter C, Whalen R, Myburgh K, et al. Bone mineral density, muscle strength, and recreational exercise in men. J Bone Miner Res 1992; 7:1291.</a></li><li><a class="nounderline abstract_t">Greendale GA, Barrett-Connor E, Edelstein S, et al. Lifetime leisure exercise and osteoporosis. The Rancho Bernardo study. Am J Epidemiol 1995; 141:951.</a></li><li><a class="nounderline abstract_t">Jackson JA, Kleerekoper M. Osteoporosis in men: diagnosis, pathophysiology, and prevention. Medicine (Baltimore) 1990; 69:137.</a></li><li><a class="nounderline abstract_t">Kujala UM, Kaprio J, Kannus P, et al. Physical activity and osteoporotic hip fracture risk in men. Arch Intern Med 2000; 160:705.</a></li><li><a class="nounderline abstract_t">Paganini-Hill A, Chao A, Ross RK, Henderson BE. Exercise and other factors in the prevention of hip fracture: the Leisure World study. Epidemiology 1991; 2:16.</a></li><li><a class="nounderline abstract_t">Joakimsen RM, Fønnebø V, Magnus JH, et al. The Tromsø Study: physical activity and the incidence of fractures in a middle-aged population. J Bone Miner Res 1998; 13:1149.</a></li><li><a class="nounderline abstract_t">Michaëlsson K, Olofsson H, Jensevik K, et al. Leisure physical activity and the risk of fracture in men. PLoS Med 2007; 4:e199.</a></li><li><a class="nounderline abstract_t">Ensrud KE, Fullman RL, Barrett-Connor E, et al. Voluntary weight reduction in older men increases hip bone loss: the osteoporotic fractures in men study. J Clin Endocrinol Metab 2005; 90:1998.</a></li><li><a class="nounderline abstract_t">De Laet C, Kanis JA, Odén A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 2005; 16:1330.</a></li><li><a class="nounderline abstract_t">Francis RM, Peacock M, Marshall DH, et al. Spinal osteoporosis in men. Bone Miner 1989; 5:347.</a></li><li><a class="nounderline abstract_t">Napoli N, Strotmeyer ES, Ensrud KE, et al. Fracture risk in diabetic elderly men: the MrOS study. Diabetologia 2014; 57:2057.</a></li><li><a class="nounderline abstract_t">Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166:495.</a></li><li><a class="nounderline abstract_t">Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 2008; 31:199.</a></li><li><a class="nounderline abstract_t">Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011; 305:2184.</a></li><li><a class="nounderline abstract_t">Pacifici R, Rothstein M, Rifas L, et al. Increased monocyte interleukin-1 activity and decreased vertebral bone density in patients with fasting idiopathic hypercalciuria. J Clin Endocrinol Metab 1990; 71:138.</a></li><li><a class="nounderline abstract_t">Weisinger JR, Alonzo E, Bellorín-Font E, et al. Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria. Kidney Int 1996; 49:244.</a></li><li><a class="nounderline abstract_t">Ghazali A, Fuentès V, Desaint C, et al. Low bone mineral density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria. J Clin Endocrinol Metab 1997; 82:32.</a></li><li><a class="nounderline abstract_t">Bataille P, Achard JM, Fournier A, et al. Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 1991; 39:1193.</a></li><li><a class="nounderline abstract_t">Borghi L, Meschi T, Guerra A, et al. Vertebral mineral content in diet-dependent and diet-independent hypercalciuria. J Urol 1991; 146:1334.</a></li><li><a class="nounderline abstract_t">Vezzoli G, Soldati L, Arcidiacono T, et al. Urinary calcium is a determinant of bone mineral density in elderly men participating in the InCHIANTI study. Kidney Int 2005; 67:2006.</a></li><li><a class="nounderline abstract_t">Kurland ES, Rosen CJ, Cosman F, et al. Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1997; 82:2799.</a></li><li><a class="nounderline abstract_t">Hills E, Dunstan CR, Wong SY, Evans RA. Bone histology in young adult osteoporosis. J Clin Pathol 1989; 42:391.</a></li><li><a class="nounderline abstract_t">de Vernejoul MC, Bielakoff J, Herve M, et al. Evidence for defective osteoblastic function. A role for alcohol and tobacco consumption in osteoporosis in middle-aged men. Clin Orthop Relat Res 1983; :107.</a></li><li><a class="nounderline abstract_t">Nordin BE, Aaron J, Speed R, et al. Bone formation and resorption as the determinants of trabecular bone volume in normal and osteoporotic men. Scott Med J 1984; 29:171.</a></li><li><a class="nounderline abstract_t">Van Pottelbergh I, Goemaere S, Zmierczak H, et al. Deficient acquisition of bone during maturation underlies idiopathic osteoporosis in men: evidence from a three-generation family study. J Bone Miner Res 2003; 18:303.</a></li></ol></div><div id="topicVersionRevision">Topic 2049 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7758434" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Osteoporosis in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7639446" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Severe osteoporosis in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6650552" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk factors for spinal osteoporosis in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9734509" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hip fracture in elderly men: the importance of subclinical vitamin D deficiency and hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10367034" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Case-control study of the pathogenesis and sequelae of symptomatic vertebral fractures in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6524364" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Longitudinal study of calcium metabolism in male puberty. I. Bone mineral content, and serum levels of alkaline phosphatase, phosphate and calcium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6240889" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Longitudinal study of calcium metabolism in male puberty. II. Relationship between mineralization and serum testosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3340782" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Vertebral bone density in children: effect of puberty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1874933" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1400871" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1400871" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3544993" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Osteoporosis in men with idiopathic hypogonadotropic hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024272" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1734250" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Osteopenia in men with a history of delayed puberty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8772591" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8686504" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Short-term effect of testosterone treatment on reduced bone density in boys with constitutional delay of puberty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17937534" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2152844" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6486591" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Marked disparity between trabecular and cortical bone loss with age in healthy men. Measurement by vertebral computed tomography and radial photon absorptiometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7950520" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893693" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Posterior-anterior and lateral dual-energy x-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2318940" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The impact of osteophytic and vascular calcifications on vertebral mineral density measurements in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16849417" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16598372" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16767524" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Endogenous sex steroids, weight change and rates of hip bone loss in older men: the MrOS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502778" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16651055" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18364385" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11120762" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12519853" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Differential effects of androgens and estrogens on bone turnover in normal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26901812" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Gonadal steroid-dependent effects on bone turnover and bone mineral density in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10523006" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hormonal and biochemical parameters in the determination of osteoporosis in elderly men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3023418" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Alterations in calcium, vitamin D, and parathyroid hormone physiology in normal men with aging: relationship to the development of senile osteopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10594158" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bone mineral density and androgen levels in elderly males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158001" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19195497" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : FRAX and its applications to clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17059373" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Predictors of non-spine fracture in elderly men: the MrOS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11397888" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2919850" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8954042" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9253305" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2674186" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9973670" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Altered bone mineral density in patients with complete androgen insensitivity syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10720035" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2048430" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10859044" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Osteoporosis and osteopenia in men with eating disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2788171" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12412167" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11575286" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10081873" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12161491" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996327" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Osteoporosis after orchiectomy for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15647578" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Risk of fracture after androgen deprivation for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11956415" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19929437" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Smoking predicts incident fractures in elderly men: Mr OS Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22466344" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1637023" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term bone loss in men: effects of genetic and environmental factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/961406" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Bone mineral losses in alcoholics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3953617" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Chronic alcoholism. Frequently overlooked cause of osteoporosis in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17341569" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Vitamin D status predicts physical performance and its decline in older persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16491287" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Calcium- and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15231008" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9278463" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19001206" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10999778" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18689393" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1466254" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Bone mineral density, muscle strength, and recreational exercise in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7741125" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Lifetime leisure exercise and osteoporosis. The Rancho Bernardo study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2189055" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Osteoporosis in men: diagnosis, pathophysiology, and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10724057" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Physical activity and osteoporotic hip fracture risk in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2021661" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Exercise and other factors in the prevention of hip fracture: the Leisure World study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9661079" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The TromsøStudy: physical activity and the incidence of fractures in a middle-aged population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17579509" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Leisure physical activity and the risk of fracture in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15671096" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Voluntary weight reduction in older men increases hip bone loss: the osteoporotic fractures in men study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15928804" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Body mass index as a predictor of fracture risk: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2720201" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Spinal osteoporosis in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24908567" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Fracture risk in diabetic elderly men: the MrOS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17575306" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18024851" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21632482" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2370292" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Increased monocyte interleukin-1 activity and decreased vertebral bone density in patients with fasting idiopathic hypercalciuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8770975" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8989228" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Low bone mineral density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1895673" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1942285" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Vertebral mineral content in diet-dependent and diet-independent hypercalciuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840051" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Urinary calcium is a determinant of bone mineral density in elderly men participating in the InCHIANTI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9284699" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Insulin-like growth factor-I in men with idiopathic osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2715352" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Bone histology in young adult osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6617002" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Evidence for defective osteoblastic function. A role for alcohol and tobacco consumption in osteoporosis in middle-aged men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6533788" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Bone formation and resorption as the determinants of trabecular bone volume in normal and osteoporotic men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12568407" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Deficient acquisition of bone during maturation underlies idiopathic osteoporosis in men: evidence from a three-generation family study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
